AGPHD1 Inhibitors
AGPHD1 inhibitors comprise a chemical class designed to selectively interfere with the enzymatic activity of the AGPHD1 protein, which is implicated in a variety of cellular processes including metabolic regulation and signal transduction. These inhibitors operate by binding to the active site or other critical regions of the AGPHD1 protein, thereby impeding its normal function. The specificity of these compounds ensures that they effectively diminish the activity of AGPHD1 without exerting widespread effects on other proteins. The design of these inhibitors is based on the protein's structure and the biochemical pathways it influences. By targeting the AGPHD1 protein, these inhibitors alter specific signaling cascades that the protein normally regulates. This can have a profound effect on cellular function, given the protein's role in modulating the activity of various downstream targets within the cell. The inhibition of AGPHD1 can lead to alterations in cellular metabolism, changes in gene expression, and modulation of other proteins that interact with AGPHD1.
The development of AGPHD1 inhibitors has required a comprehensive understanding of the protein's role at the molecular level, including the identification of its substrates and interaction partners. The binding efficiency and selectivity of these inhibitors are critical characteristics that define their effectiveness. Molecules within this class are characterized by their ability to engage with AGPHD1 in a manner that disrupts its catalytic activity, which is essential for the protein's regulatory functions. As a result, the signaling pathways that depend on the enzymatic action of AGPHD1 are affected, leading to a decrease in the protein's biological output. By inhibiting AGPHD1, these compounds can induce a cascade of downstream effects, culminating in the modulation of cellular processes that are normally under the control of AGPHD1. This precise mechanism of action makes AGPHD1 inhibitors a focus of interest for further biochemical research and a potential tool for dissecting the intricate web of cellular signaling pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
A specific mTOR inhibitor, Rapamycin binds to FKBP12 and the resulting complex inhibits mTORC1. The inactivation of mTORC1 by Rapamycin leads to a reduction in protein synthesis and cell proliferation, which indirectly inhibits the activity of AGPHD1 by limiting the cellular resources necessary for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of the PI3K/Akt pathway, LY294002 binds to the ATP-binding site of PI3K, inhibiting its activity. Since the PI3K/Akt pathway is involved in multiple cellular processes including cell growth and survival, inhibition by LY294002 can lead to reduced AGPHD1 activity as a result of decreased cellular proliferation and survival signals. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
This compound is a selective inhibitor of MEK, which subsequently prevents the activation of ERK, a downstream target involved in cell cycle progression. By inhibiting MEK and thus ERK activity, PD98059 can decrease the signaling necessary for cell growth and division, indirectly affecting the functional activity of AGPHD1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a well-known inhibitor of p38 MAPK. Given that p38 MAPK is involved in stress responses, including inflammation and apoptosis, its inhibition can reduce the overall stress response in the cell, potentially decreasing the demand for AGPHD1 function within those pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an inhibitor of PI3K, leading to the suppression of the PI3K/Akt signaling pathway. The inhibition of this pathway can lead to decreased cell survival and growth, which are indirectly related to the function of AGPHD1 by affecting the overall cellular environment in which AGPHD1 operates. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 can reduce the activity of the JNK pathway involved in cellular stress and apoptosis. By inhibiting JNK signaling, SP600125 indirectly influences AGPHD1 activity by altering the cellular response to stress where AGPHD1 may play a role. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
ZM336372 is a potent inhibitor of Raf-1 kinase, which is upstream of the MAPK/ERK pathway. Inhibition of Raf-1 can lead to decreased ERK signaling, which plays a role in cell cycle progression and differentiation, thereby affecting the functional context of AGPHD1. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib selectively inhibits EGFR tyrosine kinase, which blocks the downstream signaling pathways such as PI3K/Akt and MAPK/ERK. Reduced signaling through these pathways can decrease cellular proliferation and survival, indirectly influencing AGPHD1 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multikinase inhibitor that targets RAF kinases as well as several receptor tyrosine kinases. The inhibition of these kinases leads to a reduction in cell proliferation and angiogenesis, which can indirectly limit the functional activity of AGPHD1. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a selective inhibitor of several tyrosine kinases including BCR-ABL, c-KIT, and PDGFR. By inhibiting these kinases, Imatinib can reduce the growth and proliferation signals within the cell, indirectly affecting AGPHD1 activity. | ||||||